Literature DB >> 483276

Bleeding time in laboratory animals. III - Do tail bleeding times in rats only measure a platelet defect? (the aspirin puzzle).

E Dejana, A Quintana, A Callioni, G de Gaetano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 483276     DOI： 10.1016/0049-3848(79)90065-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  13 in total

1.  Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.

Authors:  Maithili Sashindranath; Karen M Dwyer; Shala Dezfouli; Carly Selan; Sandra Crikis; Bo Lu; Yuping Yuan; Michael J Hickey; Karlheinz Peter; Simon C Robson; Peter J Cowan; Harshal H Nandurkar
Journal:  Purinergic Signal       Date:  2017-03-25       Impact factor: 3.765

2.  A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.

Authors:  Xin Huang; Wei-Qun Ding; Joshua L Vaught; Roman F Wolf; James H Morrissey; Roger G Harrison; Stuart E Lind
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

3.  PECAM-1 (CD31) expression modulates bleeding time in vivo.

Authors:  S Mahooti; D Graesser; S Patil; P Newman; G Duncan; T Mak; J A Madri
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

4.  PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis.

Authors:  D Kolte; J W Bryant; G W Gibson; J Wang; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2012-06

5.  Rap1b is required for normal platelet function and hemostasis in mice.

Authors:  Magdalena Chrzanowska-Wodnicka; Susan S Smyth; Simone M Schoenwaelder; Thomas H Fischer; Gilbert C White
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

6.  Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Authors:  Elizabeth A Morgan; Jochen G Schneider; Timothy E Baroni; Ozge Uluçkan; Emanuela Heller; Michelle A Hurchla; Hongju Deng; Desiree Floyd; Andrew Berdy; Julie L Prior; David Piwnica-Worms; Steven L Teitelbaum; F Patrick Ross; Katherine N Weilbaecher
Journal:  FASEB J       Date:  2009-11-20       Impact factor: 5.191

7.  Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine.

Authors:  F De Clerck; Y Somers; L Van Gorp
Journal:  Agents Actions       Date:  1984-12

Review 8.  Intravenous hemostats: challenges in translation to patients.

Authors:  Margaret Lashof-Sullivan; Andrew Shoffstall; Erin Lavik
Journal:  Nanoscale       Date:  2013-10-02       Impact factor: 7.790

9.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.

Authors:  K M Hodivala-Dilke; K P McHugh; D A Tsakiris; H Rayburn; D Crowley; M Ullman-Culleré; F P Ross; B S Coller; S Teitelbaum; R O Hynes
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Authors:  Raja Prince; Luca Bologna; Mirko Manetti; Daniela Melchiorre; Irene Rosa; Natacha Dewarrat; Silvia Suardi; Poorya Amini; José A Fernández; Laurent Burnier; Claudia Quarroz; Maria Desiré Reina Caro; Yasuhiro Matsumura; Johanna A Kremer Hovinga; John H Griffin; Hans-Uwe Simon; Lidia Ibba-Manneschi; François Saller; Sara Calzavarini; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2018-01-09       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.